These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 12419345)
1. A radiometric assay for aspartoacylase activity in cultured oligodendrocytes. Madhavarao CN; Hammer JA; Quarles RH; Namboodiri MA Anal Biochem; 2002 Sep; 308(2):314-9. PubMed ID: 12419345 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical localization of aspartoacylase in the rat central nervous system. Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127 [TBL] [Abstract][Full Text] [Related]
3. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes. Baslow MH; Suckow RF; Sapirstein V; Hungund BL J Mol Neurosci; 1999; 13(1-2):47-53. PubMed ID: 10691291 [TBL] [Abstract][Full Text] [Related]
4. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375 [TBL] [Abstract][Full Text] [Related]
5. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881 [TBL] [Abstract][Full Text] [Related]
6. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
7. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013 [TBL] [Abstract][Full Text] [Related]
8. A radiometric assay for aspartoacylase activity in human fibroblasts: application for the diagnosis of Canavan's disease. Barash V; Flhor D; Morag B; Boneh A; Elpeleg ON; Gilon C Clin Chim Acta; 1991 Sep; 201(3):175-81. PubMed ID: 1756590 [TBL] [Abstract][Full Text] [Related]
9. The pathogenesis of, and pharmacological treatment for, Canavan disease. Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725 [TBL] [Abstract][Full Text] [Related]
10. Bimodal occurrence of aspartoacylase in myelin and cytosol of brain. Wang J; Matalon R; Bhatia G; Wu G; Li H; Liu T; Lu ZH; Ledeen RW J Neurochem; 2007 Apr; 101(2):448-57. PubMed ID: 17254025 [TBL] [Abstract][Full Text] [Related]
11. Endogenous aspartoacylase expression is responsive to glutamatergic activity in vitro and in vivo. Francis JS; Strande L; Pu A; Leone P Glia; 2011 Oct; 59(10):1435-46. PubMed ID: 21608034 [TBL] [Abstract][Full Text] [Related]
12. Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination. Kirmani BF; Jacobowitz DM; Namboodiri MA Brain Res Dev Brain Res; 2003 Jan; 140(1):105-15. PubMed ID: 12524181 [TBL] [Abstract][Full Text] [Related]
14. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease. Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123 [TBL] [Abstract][Full Text] [Related]
15. Murine aspartoacylase: cloning, expression and comparison with the human enzyme. Namboodiri MA; Corigliano-Murphy A; Jiang G; Rollag M; Provencio I Brain Res Mol Brain Res; 2000 May; 77(2):285-9. PubMed ID: 10837925 [TBL] [Abstract][Full Text] [Related]
16. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192 [TBL] [Abstract][Full Text] [Related]
17. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674 [TBL] [Abstract][Full Text] [Related]
18. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? Baslow MH; Guilfoyle DN Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678 [TBL] [Abstract][Full Text] [Related]
19. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model. Becker I; Wang-Eckhardt L; Eckhardt M J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891 [TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]